FDA Manufacturing Inspections Find Frequent Failure To Follow SOPs
This article was originally published in The Tan Sheet
Executive Summary
The most common concern raised by FDA in manufacturing inspections is failure to follow standard operating procedures during pharmaceutical production, FDA Office of Regulatory Affairs National Expert Investigator Robert Coleman told a recent industry/FDA joint meeting in Washington, D.C